Miracle Pharmaceuticals has discovered a cure for heart disease. Miracle conducted tests which showed that its product completely eliminated heart disease in a sample of 1,000 people at high risk for the disease. The results were very impressive. Under the present economic circumstances, Miracle expects the project will have a positive net present value assuming a price of $200 per year for the product. Miracle's forecast assumes that the Food and Drug Administration will approve the product in one year. If approval is delayed five years, the project attains the same net present value as the one year approval if the price is increased to $350 per year. Demand would be unaffected by the two prices considered. Miracle could invest $7 million in an expanded test which would assure approval in one year. From a purely economic perspective, should Miracle conduct the expanded test?